Jefferies analyst Biren Amin raised his price target for Iovance Biotherapeutics to $31 saying the FDA is likely to agree to the company's proposal to run a Phase II trial in refractory melanoma using less stringent endpoints such as response rates and duration of response versus overall survival. He believes LN-144 could provide a "compelling option for patients refractory to IO therapies." The analyst now includes estimates for the head and neck cancer indication where he added risk-adjusted peak U.S. revenue of $334M citing "early encouraging data." Amin keeps a Buy rating on Iovance.